May 18th 2023
The sale of YUTIQ® will empower EyePoint Pharmaceuticals to continue to advance its pipeline of therapeutics through the company's upcoming clinical trials.
(COPE Credit) Expert Illustrations & Commentaries™: Envisioning New Therapies for Meibomian Gland Dysfunction-Associated DED
View More
(COPE Credit) Expert Illustrations & Commentaries™: Envisioning New Therapies for Meibomian Gland Dysfunction-Associated DED
View More
(COPE Credit) Community Practice Connections™: Expert Approaches in Cataract Surgery – Managing Advances in Techniques and Technologies With an Updated Armamentarium
View More
(COPE Credit) Community Practice Connections™: Expert Approaches in Cataract Surgery – Managing Advances in Techniques and Technologies With an Updated Armamentarium
View More
(COPE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases
View More
(COPE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases
View More
(CME/CNE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases
View More
(CME/CNE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases
View More
(COPE Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
View More
(COPE Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
View More
(CME Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
View More
(CME Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
View More
(COPE Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
(COPE Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
(CME Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
(CME Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
(COPE Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(COPE Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(CME/CNE Credit) Expert Illustrations & Commentaries™: Envisioning New Therapies for Meibomian Gland Dysfunction-Associated DED
View More
(CME/CNE Credit) Expert Illustrations & Commentaries™: Envisioning New Therapies for Meibomian Gland Dysfunction-Associated DED
View More
Medical Crossfire®: Ophthalmology and Oncology Perspectives on Integrating Novel Bispecific Antibodies Into the Uveal Melanoma Treatment Paradigm
View More
Medical Crossfire®: Expert Perspectives in Geographic Atrophy – How Can We Prepare for a New Era of Treatment?
View More
(CME Credit) Community Practice Connections™: Expert Approaches in Cataract Surgery – Managing Advances in Techniques and Technologies With an Updated Armamentarium
View More
(CME Credit) Community Practice Connections™: Expert Approaches in Cataract Surgery – Managing Advances in Techniques and Technologies With an Updated Armamentarium
View More
Multidisciplinary Perspectives on Saving Sight – The Expanding Role of the Optometrist in Retinal Disease Care
05/31/2023
View More
Multidisciplinary Perspectives on Saving Sight – The Expanding Role of the Optometrist in Retinal Disease Care
05/31/2023
View More
(CME/CNE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
(CME/CNE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
(COPE Credit) Community Practice Connections™: Restoring the Surface – Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
(COPE Credit) Community Practice Connections™: Restoring the Surface – Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
Permanent J-code granted for triamcinolone acetonide injectable suspension from Bausch + Lomb
June 22nd 2022The U.S. Centers for Medicare and Medicaid Services code is effective July 1 and will enhance access to Xipere, the only therapy available in the United States for suprachoroidal use in the treatment of macular edema associated with uveitis.
Pearls for recognizing and treating uveitis
June 16th 2022Modern Retina™ Case-Based Roundtables create an environment for ophthalmology’s brightest minds to examine complex, real-world patient cases in a discussion-based setting. Led by an expert in the topic, the group dissects the case together to improve their knowledge of rare diseases and niche diagnoses. In Fort Lauderdale, Florida, Modern Retina™ hosted Uveitis Case-Based Roundtables. Moderators Thomas Albini, MD, and Eduardo Uchiyama, MD, are uveitis specialists who have encountered intriguing cases in the clinic. Attendees asked questions and reviewed imaging of the cases in hopes of improving their overall patient care. Roundtable 1, led by Dr. Albini and discussed here, investigates two intriguing cases.
New prognostic test emerges as strong predictor of metastasis of uveal melanoma
May 3rd 2022Investigators from the Karolinska Institutet and St. Erik Eye Hospital, Stockholm, Sweden, reported that they have developed a prognostic test, referred to as serUM, that they believe is a strong predictor of metastasis of uveal melanoma.
Dissecting real-world registry study of YUTIQ for chronic non-infectious posterior uveitis
October 12th 2021Ankur Shah, MD, discusses key highlights of his presentation titled "YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic non-infectious posterior uveitis," during ASRS 2021.
AAO 2020: Fingolimod for MS offers disease control with no development of uveitis
November 15th 2020Bradley Smith, MD, presents at AAO 2020 on how fingolimod 0.5 mg, a first-line treatment for multiple sclerosis, may reduce both the number of relapses and disease progression in patients with relapsing-remitting MS as well as the incidence of uveitis.
AAO 2020: Study confirms Phase III results for uveitis treatment
November 14th 2020Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.